experspadmin

Current Perspectives on BTK Inhibition and the Novel Agents
Oncology

Current Perspectives on BTK Inhibition and the Novel Agents

clinical study insights
By Anthony R. Mato, MD, MSCE
Kinase Inhibitor Intolerance in Patients With Chronic Lymphocytic Leukemia
Oncology

Kinase Inhibitor Intolerance in Patients With Chronic Lymphocytic Leukemia

patient care perspectives
By Anthony R. Mato, MD, MSCE
Optimal Sequencing of Novel Agents for Chronic Lymphocytic Leukemia
Oncology

Optimal Sequencing of Novel Agents for Chronic Lymphocytic Leukemia

clinical study insights
By Anthony R. Mato, MD, MSCE
Oncology

Initiating Novel Agents Versus Chemoimmunotherapy in the Front-line Setting

expert roundtables
By Anthony R. Mato, MD, MSCE; Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD
Oncology

IGHV Gene Mutational Status in Prognostic Testing for Chronic Lymphocytic Leukemia

clinical topic updates
By Jan A. Burger, MD, PhD
Load More